RXRX Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 10.24%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 64.71%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 7.02%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 38.99x versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of --. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 64.71%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 861.08%. Given that GT Biopharma, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe GT Biopharma, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are larger than GT Biopharma, Inc. quarterly revenues of --. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 38.99x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Hims & Hers Health, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 2.63%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat Hims & Hers Health, Inc.'s return on equity of 25.63%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 64.71%. On the other hand Hims & Hers Health, Inc. has an analysts' consensus of $44.36 which suggests that it could grow by 29.3%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Hims & Hers Health, Inc..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hims & Hers Health, Inc. has a beta of 2.414, suggesting its more volatile than the S&P 500 by 141.424%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hims & Hers Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Hims & Hers Health, Inc. pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than Hims & Hers Health, Inc. quarterly revenues of $599M. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than Hims & Hers Health, Inc.'s net income of $15.8M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Hims & Hers Health, Inc.'s PE ratio is 63.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 38.99x versus 3.85x for Hims & Hers Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

iBio, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of -5720%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat iBio, Inc.'s return on equity of -88.23%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 64.71%. On the other hand iBio, Inc. has an analysts' consensus of $4.77 which suggests that it could grow by 152.21%. Given that iBio, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe iBio, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio, Inc. has a beta of 1.135, suggesting its more volatile than the S&P 500 by 13.459%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. iBio, Inc. pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are larger than iBio, Inc. quarterly revenues of $100K. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than iBio, Inc.'s net income of -$5.7M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while iBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 38.99x versus 83.54x for iBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.